Raphaël Ho Tsong Fang
A5041869385- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- COVID-19 epidemiological studies
- Immunotherapy and Immune Responses
- SARS-CoV-2 detection and testing
- Virus-based gene therapy research
- Animal Virus Infections Studies
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Viral gastroenteritis research and epidemiology
- COVID-19 diagnosis using AI
- Tryptophan and brain disorders
- Adipokines, Inflammation, and Metabolic Diseases
- Adipose Tissue and Metabolism
- Vaccine Coverage and Hesitancy
- Clostridium difficile and Clostridium perfringens research
- Immune Cell Function and Interaction
- Respiratory viral infections research
- CAR-T cell therapy research
- Infectious Encephalopathies and Encephalitis
- Systemic Lupus Erythematosus Research
- Gut microbiota and health
- Mosquito-borne diseases and control
- HIV Research and Treatment
Infectious Disease Models and Innovative Therapies
2019-2022
Inserm
2019-2022
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
2019-2022
Université Paris-Saclay
2020-2022
CEA Paris-Saclay
2020-2022
CEA Paris-Saclay - Etablissement de Fontenay-aux-roses
2019-2021
Université Paris-Sud
2019
InnaVirVax (France)
2014
Huazhong Agricultural University
2012
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there an urgent need for a vaccine that prevents viral infection, transmission, disease. Here, we present two-component protein-based nanoparticle displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show this induces potent neutralizing antibody responses in mice, rabbits, cynomolgus macaques....
The current pandemic of coronavirus disease (COVID) 2019 constitutes a global public health issue. Regarding the emerging importance gut-lung axis in viral respiratory infections, analysis gut microbiota's composition and functional activity during severe acute syndrome 2 (SARS-CoV-2) infection might be instrumental understanding controling COVID 19. We used nonhuman primate model (the macaque), that recapitulates mild COVID-19 symptoms, to analyze effects SARS-CoV-2 on dynamic changes...
The SARS-CoV-2 pandemic has affected more than 185 million people worldwide resulting in over 4 deaths. To contain the pandemic, there is a continued need for safe vaccines that provide durable protection at low and scalable doses can be deployed easily. Here, AAVCOVID-1, an adeno-associated viral (AAV), spike-gene-based vaccine candidate demonstrates potent immunogenicity mouse non-human primates following single injection confers complete from challenge macaques. Peak neutralizing antibody...
Non-human primates infected with SARS-CoV-2 exhibit mild clinical signs. Here we used a mathematical model to characterize in detail the viral dynamics 31 cynomolgus macaques for which nasopharyngeal and tracheal load were frequently assessed. We identified that cells had large burst size (>10 4 virus) within-host reproductive basic number of approximately 6 compartment, respectively. After peak load, rapidly lost half-life 9 hours, no significant association between cytokine elevation...
Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent B.1.1.7 isolate. In both settings, SARS-CoV-2 remains undetectable lungs treated hACE2 mice. Therapeutic treatment also causes reduction viral loads Syrian hamsters. When administered at 10 mg kg-1...
Abstract The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is key for translation from promising vitro results to successful clinical implementation. Among the drugs have been largely tested trials but failed so far bring clear evidence of efficacy favipiravir, a nucleoside analogue with spectrum activity against several RNA viruses and small models. Here, we evaluate antiviral favipiravir Zika or SARS-CoV-2 virus cynomolgus macaques. In both models, high...
Abstract Achieving sufficient worldwide vaccination coverage against SARS-CoV-2 will require additional approaches to currently approved viral vector and mRNA vaccines. Subunit vaccines may have distinct advantages when immunizing vulnerable individuals, children pregnant women. Here, we present a new generation of subunit targeting antigens CD40-expressing antigen-presenting cells. We demonstrate that the receptor-binding domain (RBD) spike protein CD40 (αCD40.RBD) induces significant...
Although the metabolic properties of white adipose tissue have been extensively characterized, tissue's immune are now attracting renewed interest. Early experiments in a mouse model suggested that contains high density regulatory T cells (Tregs), and so it was assumed all has an immunosuppressive profile-even though investigation limited to visceral body fat relatively old male mice. This observation also corroborated by frequencies other cell subsets with immunoregulatory properties, such...
Abstract One year into the Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), effective treatments are still needed 1–3 . Monoclonal antibodies, given alone or as part of a therapeutic cocktail, have shown promising results in patients, raising hope that they could play an important role preventing clinical deterioration severely ill exposed, high risk individuals 4–6 Here, we evaluated prophylactic and effect COVA1-18 vivo ,...
Non-human primates (NHPs) are particularly relevant as preclinical models for SARS-CoV-2 infection and nuclear imaging may represent a valuable tool monitoring in this species. We investigated the benefit of computed X-ray tomography (CT) [18F]-FDG positron emission (PET) to monitor early phase disease large cohort (n = 76) infected macaques. Following infection, animals showed mild COVID-19 symptoms including typical lung lesions. CT scores at acute reflect heterogeneity burden following...
Abstract Non-human primates infected with SARS-CoV-2 exhibit mild clinical signs. Here we used a mathematical model to characterize in detail the viral dynamics 31 cynomolgus macaques 10 6 pfu of for which nasopharyngeal and tracheal load were frequently assessed. We identified that cells had large daily production (>10 4 virus) within-host reproductive basic number compartment, respectively. After peak load, rapidly cleared half-life 9 hours, no significant association between cytokine...
Most children are less severely affected by coronavirus-induced disease 2019 (COVID-19) than adults, and thus more difficult to study progressively. Here, we provide a neonatal nonhuman primate (NHP) deep analysis of early immune responses severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in blood mucosal tissues. In addition, comparison with SARS-CoV-2-infected adult NHP. Infection the neonate resulted mild compared NHPs that develop, most cases, moderate lung lesions....
Summary The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there an urgent need for a vaccine that prevents viral infection, transmission disease. Here, we present two-component protein-based nanoparticle displays multiple copies of the spike protein. Immunization studies show this induces potent neutralizing antibody responses in mice, rabbits cynomolgus macaques. vaccine-induced immunity protected macaques against high dose...
The SARS-CoV-2 pandemic is continuing to disrupt personal lives, global healthcare systems and economies. Hence, there an urgent need for a vaccine that prevents viral infection, transmission disease. Here, we present two-component protein-based nanoparticle displays multiple copies of the spike protein. Immunization studies show this induces potent neutralizing antibody responses in mice, rabbits cynomolgus macaques. vaccine-induced immunity protected macaques against high dose challenge,...
Abstract Controlling the circulation of recently emerged SARS-CoV-2 in human populations requires massive vaccination campaigns. Achieving sufficient worldwide coverage will require additional approaches to first generation approved viral vector and mRNA vaccines. Subunit vaccines have excellent safety efficacy records may distinct advantages, particular when immunizing individuals with vulnerabilities or considering children pregnant women. We developed a new subunit enhanced immunogenicity...